Paradigm Medical Industries is a medical device company that develops, manufactures and distributes cutting edge, new innovative products in the diagnostic ultrasound and early glaucoma detection markets. The company has the only patented technology utilizing photon lasers for cataract removal and is poised to capture a niche market within the glaucoma and ultrasound microscopy fields.

Paradigm Medical announced today that the company signed a distribution agreement with Italian company Costruzione Strumenti Oftalmici (CSO). Paradigm will distribute exclusively one of CSO’s products in the US market, Retimax, the next generation for standard ocular electrophysiology. The Retimax performs innovative tests for the early screening and follow-up of important pathologies such as: glaucoma, age-related maculopaty, vascular retinal degeneration and other optic nerve diseases.

This is an important agreement for Paradigm Medical since CSO has long been recognized as a leader in the international ophthalmic instruments market with a long history of producing safe and reliable products. As part of the agreement, Paradigm will also distribute additional ophthalmic products globally.

Paradigm Medical president Stephen Davis said, “This new partnership will create many new opportunities for both organizations. We are excited to be chosen as CSO’s exclusive distributor of their Retimax product in the domestic markets, we expect to do very well in the US. This new partnership will also open up new doors for future cooperative product development.”